Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Licht, Christoph, Greenbaum, Larry A, Muus, Petra, Babu, Sunil, Bedrosian, Camille L, Cohen, David J, Delmas, Yahsou, Douglas, Kenneth, Furman, Richard R, Gaber, Osama A, Goodship, Timothy, Herthelius, Maria, Hourmant, Maryvonne, Legendre, Christophe M, Remuzzi, Giuseppe, Sheerin, Neil, Trivelli, Antonella, Loirat, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424817/
https://www.ncbi.nlm.nih.gov/pubmed/25651368
http://dx.doi.org/10.1038/ki.2014.423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424817/
https://www.ncbi.nlm.nih.gov/pubmed/25651368
http://dx.doi.org/10.1038/ki.2014.423

Ejemplares similares